IMpassion031

NCT03197935 📎

Regimen

Experimental
Atezolizumab 840 mg Q2W + nab-paclitaxel 125 mg/m2 weekly x 12 weeks, then atezolizumab + doxorubicin/cyclophosphamide Q2W x 4 cycles, followed by surgery and adjuvant atezolizumab to complete 1 year.
Control
Same chemotherapy backbone with placebo.

Population

Previously untreated stage II-III (cT2-cT4, any N, M0) triple-negative breast cancer, regardless of PD-L1 status.

Key finding

IMpassion031 showed pCR benefit with atezolizumab + nab-paclitaxel/AC neoadjuvant in early TNBC. Conceptually confirmed the KEYNOTE-522 signal but with atezolizumab; FDA accelerated approval for TNBC was later withdrawn after IMpassion131 failed.

Source: PMID 32966830

Timeline

  • Publication: 2020 Oct 10

Guideline citations

  • NCCN BREAST